Investment
Features
FeesSafety
Academy
More
Pluang+

SOS Limited plans a 500MW AI data center campus in Indonesia's Galang Batang SEZ, pending approvals.

Company Fundamentals
18 Sep 2026
PRNewsWire
View Source
Bullish
SOS Limited plans a 500MW AI data center campus in Indonesia's Galang Batang SEZ, pending approvals.

SOS Limited's subsidiary in Singapore signed a non-binding memorandum with an Indonesian partner to develop a 500MW AI and cloud data center campus in the Galang Batang Special Economic Zone, Bintan Island. The first phase aims for 50MW capacity, targeting hyperscale and AI customers with long-term leases. The project depends on due diligence, financing, regulatory approvals, and definitive agreements. SOS highlights the strategic location near Singapore with competitive power costs and expects to fund the project through equity and project finance. The memorandum is non-binding except for certain provisions, and there is no guarantee the project will proceed as planned.

SOS Limited's AI data center plan is presented here with Pluang's Technology sector snapshot as of Sep 18, 2026 18:51 WIB. Among 150 US tech stocks, 71 rose and 71 fell. Notable movers include STM at USD 49.48 with 100% buy orders, GLW at USD 150.29 with 62% sell orders, and BTDR at USD 11.43 with 99% sell orders.

More News

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy Corporation's stock is projected to rise about 8.26% to a price target of $127, down slightly from $133, reflecting confidence despite a recent price dip. The company expects a 4.42% increase in earnings per share to $1.89 and a 3.86% ris...

Analyst Insights
Bullish
1 hour ago
Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals halted new patient enrollment in its psychiatry clinical trials for the drug azetukalner after reports of neuropsychiatric side effects. This pause led to a sharp 27.6% drop in its stock price, marking its worst day since 2017. ...

Market News
Bearish
2 hours ago
Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma reported an EPS of -$0.24, beating analyst estimates of -$0.29, and revenue of $6.5 million, slightly above expectations. The company secured a strategic partnership with Sobi for its drug lacutamab, receiving a $75 million upfront paym...

Company Fundamentals
Bullish
2 hours ago
Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex, a provider of human capital management solutions, will release its Q1 fiscal 2027 earnings on September 23, 2026. Analysts expect earnings per share (EPS) of $1.32, up from $1.22 last year, and revenue of about $1.63 billion, higher than las...

Company Fundamentals
Bullish
3 hours ago
Lennox declares quarterly dividend of $1.36 per share payable October 15, 2026

Lennox declares quarterly dividend of $1.36 per share payable October 15, 2026

Lennox's board approved a quarterly cash dividend of $1.36 per share, payable on October 15, 2026, to shareholders recorded by September 30, 2026. This dividend reflects Lennox's ongoing commitment to returning value to its investors. Lennox is a lea...

Company Fundamentals
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App